BofA analyst Alec Stranahan lowered the firm’s price target on Caribou Biosciences (CRBU) to $11 from $13 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investor focus,” the analyst tells investors in a sector outlook note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences price target raised to $34 from $26 at Brookline
- Caribou Biosciences Appoints New CFO Amid Clinical Advancements
- Caribou Biosciences appoints Sri Ryali as CFO
- Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky LLP Before February 24, 2025 to Discuss Your Rights – CRBU
- Caribou (CRBU) Develops Transformative Cell Therapies and Captures Investors’ Attention